Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS)

Abstract Introduction Enfortumab vedotin plus pembrolizumab (EVP) is the standard first-line treatment for metastatic or locally advanced urothelial carcinoma (m/laUC). Real-world patients frequently present with unfavorable clinical characteristics, raising uncertainty about whether outcomes mirror...

Cur síos iomlán

Sonraí bibleagrafaíochta

Príomhchruthaitheoirí:	Stefanie Zschäbitz, Irfan Bhatti, Jozefina Casuscelli, Ludwig Otto Pachmayr, Thomas Büttner, Thomas Elegeert, Nina Holzwarth, Severin Rodler, Martin Hennig, Emily Rinderknecht, Muammar Dib, Katrin Schlack, Christopher Darr, Anna-Lisa Volk, Philipp Schmucker, Friedemann Zengerling, Pia Paffenholz, Joschka Heil, Eva Erne, Subhajit Mandal, Frederik Wessels, Thea Maria Busse, Daniel Seidl, Susan Foller, Alexander Höllein, Tim Nestler, Christian Gratzke, Louis Rhode, Jakob Kohler, Günter Niegisch, Anna Katharina Seitz, Julia Heinzelbecker, Niklas Klümper, Margitta Retz, Viktor Grünwald, Can Aydogdu, Marco Julius Schnabel
Formáid:	Artigo
Teanga:	Inglês
Foilsithe / Cruthaithe:	Springer 2026-07-01
Sraith:	Cancer Immunology, Immunotherapy
Ábhair:	Bladder cancer Enfortumab vedotin Pembrolizumab Real world evidence Urothelial carcinoma
Rochtain ar líne:	https://doi.org/10.1007/s00262-026-04448-2
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!